CytRx Corp. says it will release data from a clinical trial on ALS at a conference later this month.
The trial data will detail the success rates of the company’s drug, arimoclomol, in treating Lou Gehrig’s disease, a progressive brain disease that results in loss of muscle tissue.
The Los Angeles-based firm has its drug discovery arm, CytRx Laboratories, in Worcester. The conference is scheduled for Sep. 26 in New York.
